Table 2

Baseline main metabolic characteristics of HIV-infected patients based on rs10892151 genotype and treatment strategy

PI-treated patients

(n = 95)

NNRTI-treated patients

(n = 113)


G/G carriers

(n = 87)

A/G carriers

(n = 8)

G/G carriers

(n = 103)

A/G carriers

(n = 10)


BMI, kg/m2

22.9 (3.1)

23.4 (3.2)

22.6 (2.9)

23.1 (3.1)

ApoC-III, μg/mL

11.12 (5.1)

10.62 (4.6)

11.39 (4.9)

10.26 (4.8)

Total cholesterol, mmol/L

4.91 (1.3)

5.06 (1.3)

4.87 (1.2)

4.60 (1.2)

HDL-cholesterol, mmol/L

1.02 (0.4)

1.06 (0.4)

1.09 (0.4)

1.1 (0.4)

VLDL-cholesterol, mmol/L

0.82 (0.2)

0.54 (0.1)

0.91 (0.4)

0.72 (0.3)

LDL-cholesterol, mmol/L

2.82 (0.8)

2.87 (0.9)

2.88 (0.9)

2.95 (0.9)

Triglycerides, mmol/L

2.65 (2.1)

2.78 (2.2)

2.34 (2.2)

2.10 (2.1)

Glucose, mmol/L

5.68 (1.0)

5.95 (0.9)

5.15 (0.9)

5.16 (0.9)

CRP, mg/L

4.6 (5.4)

5.1 (5.6)

3.73 (5.5)

4.76 (5.7)

MCP-1, pg/mL

73.31 (40.3)

78.76 (43.8)

75.92 (42.1)

83.10 (44.8)


Values are the mean and the standard deviation (SD), unless otherwise indicated. BMI, body-mass index; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcritase inhibitor

Aragonès et al. BMC Medical Genetics 2011 12:120   doi:10.1186/1471-2350-12-120

Open Data